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Protectionr controlling Classical Swine Fever Virus (CSFV) involve either prophylactic
vaccination or non-vaccination with elimination of infected herds depending on the epidemiological
situation of the affected geographical area. Marker vaccines allowing distinction between naturally infected
from vaccinated swine could complement “stamping out” measures. Here we developed a double antigenic
marker live attenuated CSFV strain FlagT4v obtained by combining two genetic determinants of attenuation.
FlagT4v harbors a positive antigenic marker, synthetic Flag® epitope, introduced via a 19mer insertion in E1
glycoprotein; and a negative marker resulting from mutations of the binding site of monoclonal antibody
WH303 (mAbWH303) epitope in E2 glycoprotein. Intranasal or intramuscular administration of FlagT4v
protected swine against virulent CSFV Brescia strain at early (2 or 3 days), and late (28 days) time post-
inoculation. FlagT4v induced antibody response in pigs reacted strongly against the Flag® epitope but failed
to inhibit binding of mAbWH303 to a synthetic peptide representing the WH303 epitope. These results
constitute a proof-of-concept for rationally designing a CSFV antigenically marked live attenuated virus.
Published by Elsevier Inc.IntroductionClassical swine fever (CSF) is a highly contagious disease of swine.
The etiological agent, CSF virus (CSFV), is a small, enveloped virus with
a positive, single-stranded RNA genome, classiﬁed as a member of the
genus Pestiviruswithin the family Flaviridae (Fauquet et al., 2005). The
12.5 kb CSFV genome contains a single open reading frame that
encodes a 3898-amino-acid polyprotein and ultimately yields 11 to 12
ﬁnal cleavage products (NH2–Npro–C–Erns–E1–E2–p7–NS2–NS3–
NS4A–NS4B–NS5A–NS5B–COOH) through co- and post-translational
processing of the polyprotein by cellular and viral proteases (Rice,
1996). Structural components of the CSFV virion include the capsid (C)
protein and glycoproteins Erns, E1, and E2. E1 and E2 are anchored to
the envelope at their carboxyl termini and Erns loosely associates with
the viral envelope (Thiel et al., 1991; Weiland et al., 1990; 1999). E1Holinka),
z),
arat@ars.usda.gov
), zlu@dhs.gov (Z. Lu),
@ars.usda.gov (M.V. Borca).
.
nc.and E2 are type I transmembrane proteins with an N-terminal
ectodomain and a C-terminal hydrophobic anchor (Thiel et al., 1991).
E2 is the most immunogenic of the CSFV glycoproteins (Konig et al.,
1995; van Gennip et al., 2000; Weiland et al., 1990), inducing
neutralizing antibodies, which provide protection against lethal
CSFV challenge.
The two main policies used for CSFV control are prophylactic
vaccination or non-vaccination with “stamping out” of exposed
animals in the event of an outbreak. Countries considered free of
CSF do not recommend the use of currently available live attenuated
viruses (LAVs) as tools to control outbreaks of the disease, despite the
proven efﬁcacy of these vaccines in eliciting a rapid and solid
protection against the virus (van Oirschot, 2003). The humoral
immune response induced by these vaccines does not differ from
that elicited by infections caused by wild-type viruses; hence, the use
of CSFV LAVs has been hampered by their inability of inducing a
response differentiable between infected and vaccinated animals
(DIVA capability). Thus, the use of a CSFV LAV with DIVA capabilities
could signiﬁcantly impact policies of disease control. CSFV subunit
marker vaccines with DIVA capabilities have been developed using
recombinant CSFV E2 envelope protein (Hulst et al., 1993; van Rijn et
al., 1996; 1999). The onset of immunity elicited by subunit vaccines
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traditional LAV vaccines when animals are exposed to CSFV shortly
after vaccination (Bouma et al., 2000; Uttenthal et al., 2001).
Infectious clone technology has recently enabled antigenic
modiﬁcation of attenuated CSFV strains for use as experimental LAV
marker vaccines. Infectious clones of the C-strain have been used to
replace the antigenic region of E2 and/or the complete Erns gene with
analogous sequences derived from Bovine Viral Diarrhea Virus (BVDV)
(van Gennip et al., 2000). Also, promising experimental results were
obtained with chimeric viruses using a BVDV infectious clone where
the E2 gene was replaced with analogous sequences derived from
CSFV strain Alfort (Reimann et al., 2004). Preliminary data suggest
that all these chimeric vaccine viruses were able to induce protection
in pigs and, signiﬁcantly, chimera-induced anti-CSFV antibody
responses could be discriminated from those produced by parental
viruses.
In this study, we present the development of a CSFV experimental
marker LAV strain, FlagT4v, containing the inserted synthetic epitope,
Flag® (Sigma, St. Louis, MO), that serves as a positive antigenic marker,
and the abolition of a highly conserved CSFV-speciﬁc epitope
recognized by monoclonal antibody WH303 (mAbWH303e), that
serves as a negative antigenic marker (Edwards et al., 1991). Intranasal
immunization with FlagT4v induced complete protection against
challenge with virulent CSFV Brescia, both at 3 and 28 days post-
infection (DPI). Intramuscular administration of FlagT4v to swine
elicited complete protection against CSFV Brescia starting 2 DPI.
Serological responses against both the Flag and mAbWH303 epitopes
in animals immunized with FlagT4v allowed the discrimination of
animals immunized with FlagT4v from animals challenged with CSFV
Brescia. Furthermore, novel real-time reverse transcriptase polymer-
ase chain reaction (rtRT-PCR) assays accurately distinguished FlagT4v
and wild-type CSFV Brescia RNAs.
Results
Rescue of FlagT4v
Infectious RNA was in vitro transcribed from full-length ICs of the
FlagT4v (Fig. 1) and used to transfect SK6 cells as described earlier
(Risatti et al., 2005a). Viruses were rescued from transfected cells by
day 4 post-transfection. Full-length nucleotide sequences of the
rescued virus genomes were identical to parental DNA plasmids,
conﬁrming that only predicted mutations were reﬂected in rescued
viruses.
In vitro growth characteristics of FlagT4vwere evaluated relative to
parental BICv in a single-step growth curve. SK6 cell cultures were
infected at a multiplicity of infection (MOI) of 0.01 TCID50 per cell.
Virus was adsorbed for 1 h (time zero), and samples were collected at
72 h post-infection (PI). Samples were titrated in SK6 cells, the
presence of virus detected by immunoperoxidase, and titers calcu-
lated as described by Risatti et al. (2005a). Results (data not shown)
showed that FlagT4v had an approximately 10-fold decrease in the
ﬁnal virus progeny yield relative to parental BICv (reaching titers of 5.2
(SD: ±0.45) TCID50/ml and 6.04 (SD: ±0.07), respectively).
Additionally, FlagT4v was tested for the ability to form plaques in
SK6 cells, exhibiting a signiﬁcant reduction in plaque size relative to
BICv (Fig. 3). This small plaque phenotype is expected since both
parental viruses, RB-C22v and T4v, showed small plaque phenotypes
relative to the parental virus BICv in SK6 cultures (Risatti et al., 2005b;
2006).
The antigenic proﬁle of FlagT4v was evaluated regarding its
reactivity against monoclonal antibodies (mAbs) anti-Flag, WH303,
and WH174. FlagT4v strongly reacted with mAbs anti-Flag and
WH174, while completely lacking reactivity with mAb WH303.
Conversely, BICv reacted with both mAbs WH303 and WH174, but
failed to react with mAb anti-Flag (Fig. 1B).FlagT4v protects pigs against lethal CSFV challenge
The ability of FlagT4v to induce protection against virulent BICv
was assessed in early and late vaccination-exposure experiments.
Groups of pigs (n=4) were intranasally (IN) inoculated with FlagT4v
and challenged at 3 or 28 DPI. Mock-vaccinated control pigs receiving
BICv only (n=4) developed anorexia, depression, and fever by 4 days
post-challenge (DPC), a marked reduction of circulating leukocytes
and platelets by 4 DPC (Fig. 2), and died or were euthanized in extremis
by 8–10 DPC. Notably, FlagT4v induced complete clinical protection
within 3 days after immunization. All pigs survived infection and
remained clinically normal, without fever or signiﬁcant changes in
their hematological values (Fig. 2). Pigs challenged at 28 days post-
FlagT4v-infection were also protected, remaining clinically normal,
with no alterations of hematological proﬁles (Fig. 2) or presence of
fever. Viremia and virus shedding of vaccinated and challenged
exposed animals were examined at 3, 4, 6, 8, 12, 14 and 21 DPC.
Detectionwas performed usingmAbWH303, which reacts speciﬁcally
with the challenge virus BICv. As expected, inmock-vaccinated control
animals, viremia was observed within 4 days after challenge, with
virus titers remaining high by 8 DPC, the last time point tested before
animals died or were euthanized. Furthermore, the challenge virus
was detected in nasal swabs and tonsil scrapings of mock-vaccinated
between 4 and 8 DPC. Conversely, animals inoculated with FlagT4v
and challenged with BICv at 3 or 28 DPI did not present viremia or
virus shedding. BICv was not detected in nasal, tonsil or blood samples
during the 21-day observation period. These results indicate that
protection induced by FlagT4v was complete, preventing both the
presentation of CSF-related clinical signs and the replication of the
challenge virus.
Intranasally inoculated, CSFV Brescia replicates primarily in
tonsils, and then the infection expands to secondary target lymphoid
organs (Risatti et al., 2005a; 2005b; 2006). Thus, CSFV replication in
tonsils seems to be a critical step before generalization of the
infection in pigs after IN inoculation. To understand mechanisms
mediating early protection we looked into the early events of CSFV
replication that take place in the host soon after IN inoculation. The
simultaneous presence of both FlagT4v and BICv in the main target
organs including palatine tonsil, mandibular and retropharyngeal
lymph nodes, and spleen was analyzed at different time points after
infection with FlagT4v or BICv. Three groups of animals were IN
inoculated with 105 TCID50 of either FlagT4v or BICv, or received
FlagT4v followed by challenge with BICv at 3 DPI. Two animals from
each of the groups inoculated with FlagT4v or BICv were euthanized
at 3, 5 and 7 DPI. Pigs in the exposure-challenge group were
euthanized at days 1, 3, 5, and 7 after receiving the BICv challenge.
Tonsils, mandibular lymph nodes (MLN), retropharyngeal lymph
nodes (RPLN), and spleen were removed from all animals immedi-
ately at necropsy. The presence of each virus in all collected organs
was examined by virus titration in SK6 cells. As expected, in animals
inoculated with BICv, virus titers were detected in tonsils at 3 DPI,
increasing signiﬁcantly at 5 and 7 DPI (Table 1). In this group of
animals, titers of BICv also increased in draining retropharyngeal and
mandibular lymph nodes, as well as in spleen, from 3 DPI to 7 DPI
(Table 1). Animals infected with FlagT4v showed virus titers, as
detected with mAb anti-Flag, in tonsils by 3 DPI increasing slightly
towards 5 and 7 DPI, albeit the magnitude of these titers were 100-
fold lower relative to virus titers observed in tonsils derived from
animals inoculated with BICv (Table 1). Furthermore, titers of FlagT4v
were also reduced 100-fold in retropharyngeal and mandibular
lymph nodes relative to BICv infected animals, and detected only at 3
and 5 DPI (Table 1). FlagT4v was not detected in spleen samples.
Altogether the results indicate that when inoculated IN, FlagT4v
remains restricted to tonsils and the regional draining lymph nodes.
Remarkably, all tissue samples obtained from animals of the FlagT4v
infected/BICv challenged group were negative for BICv, as detected
Fig.1. (A) Schematic representation of the Flag virus. Flag virus is a derivative of CSFV RB-C22v (Risatti et al., 2005b) (top panel) where a portion of the 19mer insert has been replaced
by the Flag epitope (depicted in italics, bottom panel). (B) Schematic representation of the FlagT4 virus (top panel). The CSFV mAbWH303 epitope is shown along with its modiﬁed
version (depicted in italics) where the mAbWH303 reactivity has been abolished (Risatti et al., 2006). Antigenic phenotype of FlagT4 and BIC viruses (bottom panel). SK6monolayers
were infected, overlaid with 0.5% agarose and incubated at 37 °C for 3 days. Plates were ﬁxed with 50% (vol/vol) ethanol–acetone and stained by immunohistochemistry with mAbs
WH303, anti-Flag or WH174. BICv and FlagT4v plaques are shown at 1× and 100× magniﬁcations, respectively.
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Fig. 2. (A) Peripheral white blood cell, (B) platelet, and (C) lymphocyte counts in
peripheral blood obtained from pigs inoculated intranasally with virulent BICv, FlagT4v
or inoculated with FlagT4v and then challenged with virulent BICv at 3 and 28 days
post-inoculation. Counts are expressed as numbers of cells/ul and represent the mean
with error bars indicating standard error.
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These results would suggest that after challenge, BICv does not
replicate in FlagT4v infected animals (sensitivity of detection N1.8
TCID50/ml).
To further conﬁrm these results, the presence of FlagT4v and BICv
in tonsils was assessed by immunoﬂuorescence using mAbs anti-Flag
or WH303. Results corroborate previous observations. Tonsils from
animals infected with FlagT4v showed a weak but clear ﬂuorescent
signal with mAb anti-Flag in samples obtained at 3, 5 and 7 DPI.
Moreover, tonsils obtained from BICv-infected animals showed strong
reactivity with mAb WH303 at all days tested. Furthermore, FlagT4v
was detected in tonsils obtained from animals in the FlagT4v-infected/BICv-challenged group, whereas no signal was observed
when using mAbWH303 at any of the tested time points (1, 3, 5 and 7
DPC).
Intramuscular (IM) administration of FlagT4v induces protection 2 days
after challenge with virulent CSFV
The early induction of protection after vaccination is of paramount
importance during a disease outbreak. Therefore, the ability of FlagT4v
on inducing protection earlier than 3 DPC was evaluated in a
vaccination/challenge experiment. Five groups of animals (n=4)
were IM inoculated with 105 TCID50 of FlagT4v and challenged via
IN inoculation with 105 TCID50 BICv at 0, 24, 48, or 72 h post-
vaccination. Interestingly, animals challenged at 48 or 72 h after
FlagT4v inoculation remained clinically normal during the 21-day
experimental period. Three of the animals challenged at 24 h after
FlagT4v infection presented CSFV clinical signs and were euthanized
by 15 DPC, while the other one remained clinically normal. Animals
infected/challenged simultaneously (day 0) presented disease kinetics
indistinguishable relative to the mock-vaccinated/challenged group
(Table 2).
Differential antibody responses in FlagT4v inoculated pigs
The anti-Flag serological response in animals infected with FlagT4v
via IN or IM routes was tested at 28 DPI using an in-house ELISA assay.
Animals infected by IN (N=4) and IM (N=3) routes developed a strong
anti-Flag antibody response with average titers of (log10) 2.67 (SD
0.07) or (log10) 2.71 (SD 0.08), respectively. Sera from animals infected
with viruses lacking the Flag epitope presented OD readings
comparable with those obtained with non-immune sera (Fig. 3B).
The presence of an anti-mAbWH303e antibody response was
analyzed in FlagT4v vaccinated animals (N=7) also at 28 DPI. An in-
house competitive ELISA test was developed, where the ability of
mAbWH303 labeled with HRP to bind to a peptide, representing
mAbWH303e, would be out-competed with sera derived from pigs
immunized with FlagT4v or with sera derived from pigs infected with
viruses harboring an unmodiﬁed mAbWH303e. Results showed that
the sera from FlagT4v-infected animals (N=7) were as unable to
compete with mAbWH303 as a group of sera obtained from mock-
infected pigs (N=4) was, indicating a lack of anti-mAb303e antibodies
(Fig. 3A). Conversely, a pool of sera (N=4) obtained from animals
infected with viruses harboring an unaltered mAbWH303e efﬁciently
out-competed the HRP-labeled mAbWH303, precluding binding with
mAbWH303e (Fig. 3A). Interestingly, sera obtained from seven
animals vaccinated with FlagT4v 21 days after challenge with BICv
showed a slightly increased ability to compete with mAbWH303. It is
important to notice that with the exception of the mock-infected sera,
all sera used here showed anti-CSFV activity as determined by Checkit
CSFV-sero (IDEXX, The Netherlands) and virus seroneutralization
assays (data not shown). Taken together, the serological results
showed that FlagT4v was able to induce a speciﬁc antibody response
by 28 DPI that was distinguishable from the antibody response
induced by BICv-derived viruses lacking a Flag epitope but harboring
an intact mAbWH303e.
Genetic based distinction between FlagT4v and BICv
We used an rtRT-PCR TaqMan® based approach to distinguish
between isolated FlagT4v and BICv. A duplex one-step rtRT-PCR was
designed using TaqMan® probes, labeled with TET or 6FAM ﬂuor-
ochromes, targeting the genomic regions encoding for the Flag
epitope in FlagT4v and the genomic region encoding formAbWH303e.
Combination of primers, probes, with RNA from either of the viruses in
independent reactions allowed distinction between FlagT4v (6FAM
channel) and BICv (TETchannel). Signals were observed only when the
Table 1
Titration in tissue samples and detection by immunoﬂuorescence (IFA) of FlagT4 and BIC viruses in organs of animals intranasally inoculated with FlagT4v, BICv or inoculated with
FlagT4v followed by a challenge with BICv at 3 days post-inoculation
Virus Log10 TCID50/g IFA(c)
DPI Tonsils RPLN MLN Spleen mAb anti-Flag mAbWH303
FlagT4v (a) 3 2.1 (0.2) nd 1.9 (0) nd +\+ nd/nd
5 4.8 (0) 2.6 (0.6) 2.1 (0.2) nd ++\++ nd/nd
7 4.1 (1.6) nd nd nd +\ND nd/nd
BICv (b) 3 4.4 (1) 2.6 (0.4) 2.88 (0.3) 2.1 (0.1) nd\nd ++/++
5 6.3 (0) 4.3 (0) 4.6 (0.7) 4.5 (0) nd\nd ++/++
7 6.9 (0.8) 6.3 (0.2) 6.9 (1.1) 6.2 (1) nd\nd +++/+++
DPC Tonsils RFLN MLN Spleen mAb anti-Flag mAbWH303
FlagT4v/BICv (b) 1 nd nd nd nd ++/+ nd/nd
3 nd nd nd nd ++/++ nd/nd
5 nd nd nd nd ++/ND nd/nd
7 nd nd nd nd ++/+ nd/nd
References: (a) Virus titers detected with mAb anti-Flag or (b) with mAb WH303. Values in parentheses are standard deviation for 2 animals. ND: not determined. (c)
Immunoﬂuorescence in tonsil tissues obtained from two animals per time point was estimated from low (+) to strong (+++) reactivity. DPI: days post-infection. DPC: days post-
challenge with BICv. nd: (not detectable) virus titers b1.8 TCID50 (log10). RPLN: retropharyngeal lymph node. MLN: mandibular lymph node.
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of the assay (Fig. 4).
Discussion
We present here an approach for rationally developing of an
experimental live attenuated marker CSFV vaccine strain. The
candidate vaccine virus, FlagT4v, harbors functional positive and
negative antigenicmarkers that confer potential DIVA capabilities. The
virus elicits solid protection against challenge with highly virulent
BICv (Brescia strain) by 3 DPI when administered intranasally, or as
early as 2 DPI when administered intramuscularly in swine. Response
to FlagT4v can be distinguished from awild-type CSF virus (i.e., Brescia
strain) by means of serology.
The majority of CSF control programs in enzootic areas are based
on prophylactic vaccination of domestic pigs. Vaccination with live
attenuated vaccine (LAV) strains induce protective immunity in pigs
within a few days after vaccination, even before neutralizing
antibodies can be detected, providing lifelong immunity against
disease (Biront and Leunen, 1988; Terpstra, 1991). However, current
LAVs lack DIVA capabilities that would allow differentiation between
infected and vaccinated animals, limiting their use as an emergency
control strategy in the event of an outbreak in CSFV-free regions. CSFV
subunit marker vaccines with DIVA capabilities have been developed
using recombinant E2 envelope protein (Hulst et al., 1993; van Rijn et
al., 1996; 1999). These vaccines are commercially available and have
proven to induce solid and long lasting immunity approximately
2 weeks after vaccination. This delayed onset of immunity against
CSFV makes them undesirable for use in emergency vaccination
programs (Bouma et al., 2000; Uttenthal et al., 2001). Thus, there is
an increased need for developing LAVs against CSFV with DIVATable 2
Survival, CSF clinical signs, and fever response of swine intramuscularly inoculated with
FlagT4v and challenged intranasally with virulent BICv at times post-inoculation.
Challenge time
(DPI)
No.
survivors/
total
CSF signs/
time of death
Days (SD)
Mean time
of fever
onset Days
(SD)
Mean time
of duration
of fever
Days (SD)
Max daily
temperature
(°C)
0 0/4 Yes/10 (1.2) 4 (0.8) 5.2 (2.1) 40.9
1 1/4 Yes/13.6 (1.5) 6.2 (2.5) 5 (3.7) 41.1
2 4/4 No/No No/No No/No 39.5
3 4/4 No/No No/No No/No 39.5
28 4/4 No/No No/No No/No 39
Mock-inoculated 0/4 Yes/9.5 (07) 4.5 (0.7) 5 (1.4) 40.8
References: DPI: days post-FlagT4v inoculation. SD: standard deviation.capabilities (Beer et al., 2007; Dong and Chen, 2007). These vaccines,
while inducing a rapid and effective immunity, should harbor
antigenic markers for serological distinction of infected from
vaccinated animals. In addition, a rapid molecular diagnostic test,
such as real-time RT-PCR, should accurately distinguish vaccinated
and wild-type infected ﬁeld isolates.
FlagT4v has been developed using this approach. Attenuation of
FlagT4vwas achieved bymanipulating two independent novel genetic
determinants of viral virulence (Risatti et al., 2005b; 2006). So far,
experimental CSFV LAV candidates have been designed based on the
use of the genetic backgrounds of known LAV CSFV vaccine strains
(van Gennip et al., 2000;Wehrle et al., 2007) or other Pestiviruses (i.e.,
BVDV) that replicate in pigs without causing disease (Reimann et al.,
2004). The genetic determinants of attenuation in these two
approaches remain to be elucidated.
Early protection is a critical aspect to be addressed in development
of novel LAVs for use during a CSFV outbreak in areas free of disease.
Most CSFV experimental vaccines developed to date have been tested
for their potency against challenge between 2 to 4 weeks post-
vaccination, lacking data about how efﬁcacious these vaccines are if
tested in shorter vaccination-to-exposure trials that eventually will
make them suitable for emergency vaccination. Notably, FlagT4v is
able to induce a solid protection status in swine from day 3 post-
inoculation when administered intranasally, or from day 2 post-
inoculation when delivered intramuscularly. Replication of challenge
virus in FlagT4v-inoculated animals appears to be severely restricted
or completely undetectable (Tables 1). Immune mechanisms mediat-
ing this early protection are still unknown. It is possible that an
effect compatible with interference mediated by direct competition
between FlagT4v and BICv might occur, where a combination of
mechanisms such as direct occupancy of target cells by FlagT4v
precluding entry of BICv or release of soluble inhibitory factors from
FlagT4-infected cells are involved.
FlagT4v-infected animals develop a serological antibody response
that, analyzed at 28 DPI, allows a differentiation relative to the
serologic proﬁle observed in mock-vaccinated animals or in animals
infected with attenuated CSF viruses lacking the antigenic markers.
Therefore, anti-Flag antibodies were readily detected in all FlagT4v-
infected animals showing titers reaching above (log10) 2.00, while
anti-CSFV sera (positive by commercial ELISA tests) lacked anti-Flag
reactivity comparable to sera obtained from mock-infected animals.
Similarly, no reactivity was detected in sera obtained from FlagT4v
(also positive by commercial ELISA tests) or mock-infected animals
against the mAbWH303e; reactivity against this epitope was detected
in sera obtained from animals infected with viruses harboring an
intact mAbWH303e. Besides the distinctive serological proﬁle elicited
Fig. 3. Antibody response in animals infected with FlagT4v. (A) Antibody response
against mAbWH303e in sera obtained from animals (N=7) at 28 days after infection
with FlagT4v (FlagT4v-infected); in sera obtained from animals at 21 days after
challenge (FlagT4v-challenged); in pooled CSFV positive sera obtained from animals
(N=4) at 28 days after infection with attenuated recombinant viruses derived from
strain Brescia harboring intact mAbWH303e (positive sera); or in sera obtained from
mock infected animals (N=4) (negative sera). Results are presented as rough OD values.
(B) Anti-Flag antibody response at 28 days after infection with FlagT4v in animals
inoculated intranasally (IN.1 through IN.4); intramuscularly (IM.1 through IM.3); or in
animals inoculated with attenuated recombinant viruses derived from strain Brescia
lacking the Flag epitope (PC.1 through PC.3). Titers are presented as log10 of the inverse
of the highest dilution that doubles the OD values obtained with a pool of CSFV negative
sera obtained from mock-infected animals.
Fig. 4. Differential detection of FlagT4v and BICv by real time RT-PCR. Detection of (A)
BICv RNA or (B) Flag T4v RNA in a duplex TaqMan® rtRT-PCR containing both FAM
labeled (FlagT4v) and TET labeled (BICv) probes and primer sets.
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means (Fig. 4).
In summary, we present here the development of a rationally
designed CSFV double antigenically marked experimental vaccine
with DIVA capabilities. The candidate vaccine virus is able to induce
protection against challenge with a highly virulent strain of CSFV, and
elicits an antibody response that can be differentiated from the
response induced by the wild-type virus.
Materials and methods
Viruses and cells
Swine kidney cells (SK6) (Terpstra et al., 1990), free of BVDV, were
cultured in Dulbecco's minimal essential media (DMEM) (Gibco,
Grand Island, NY) with 10% fetal calf serum (FCS) (Atlas Biologicals,
Fort Collins, CO). CSFV derived from full-length cDNA copies, including
CSFV Brescia strain (BICv) (Risatti et al., 2005a), RB-C22v (Risatti et al.,
2005b), T4v (Risatti et al., 2006), and FlagT4v (this study) werepropagated in SK6 cells. Titration of CSFV from clinical samples was
performed using SK6 cells in 96-well plates (Costar, Cambridge, MA).
Viral infectivity was detected, after 4 days in culture, by an
immunoperoxidase assay using the CSFV monoclonal antibody
(mAb) WH174 (kindly provided by Georgina Ibata, Veterinary
Laboratory Agency, UK) or mAb WH303, and the Vectastain ABC kit
(Vector Laboratories, Burlingame, CA). Titers were calculated using the
method of Reed and Muench (1938) and expressed as TCID50/ml. As
performed, test sensitivity was N1.8 TCID50/ml. Plaque assays were
performed using SK6 cells in 6-well plates (Costar). SK6 monolayers
were infected, overlaid with 0.5% agarose and incubated at 37 °C for
3 days. Plates were ﬁxed with 50% (vol/vol) ethanol–acetone and
stained by immunohistochemistry with mAbs WH174, WH303
(Edwards et al., 1991) or anti-Flag (Sigma, St. Louis, MO).
Construction of CSFV FlagT4v
A full-length cDNA copy of RB-C22v (Risatti et al., 2005b) was NotI–
NheI digested and the excised 46 nucleotide fragment replaced with an
oligonucleotide, forward sequence 5′ GGCCGCAGATTACAAGGATGAC-
GACGATAAGGGGGCAC AAGGCCGG 3′ and reverse complementary
sequence 5′ CTAGCCGGCCTTGTGCCC CCTTATCGTCGTCATCCTTGTAATC-
TGC 3′, encoding for the Flag epitope DYKDDDDK (bold case) (Fig 1A).
One hundred picomoles of the forward and reverse oligonucleotides
were annealed in buffer containing 10mMTris, pH 7.5–8.0, 50mMNaCl,
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cooled at room temperature for 30 min. Annealed oligonucleotides
were directionally cloned into NotI–NheI digested pRB-C22 using T4
DNA ligase (New England Biolabs, Beverley, MA). The introduction of
mutations in amino acids at positions 829 to 834 of the CSFV
polyprotein resulting in a shift of the Brescia amino acid sequence
(TAVSPT) to the corresponding residues in bovine viral diarrhea virus
(BVDV) strain NADL (TSFNMD) were performed on the pFlag-T4 exactly
as described by Risatti et al. (2006) for the development of the T4 virus
(Fig. 1B).
In vitro rescue of CSFV Brescia and FlagT4v
Full-length genomic clones were linearized with SrfI and in vitro
transcribed using the T7Megascript system (Ambion, Austin, TX). RNA
was precipitated with LiCl and transfected into SK6 cells by
electroporation at 500 V, 720 ohm, 100 W, with a BTX 630
electroporator (BTX, San Diego, CA). Cells were seeded in 12-well
plates and incubated for 4 days at 37 °C and 5% CO2. Virus was detected
by immunoperoxidase staining as described above, and stocks of
rescued viruses were stored at −70 °C.
DNA sequencing and analysis
Full-length clones and in vitro rescued viruses were completely
sequenced with CSFV-speciﬁc primers by the dideoxynucleotide
chain-termination method (Sanger et al., 1977). Sequencing reactions
were preparedwith the Dye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA). Reaction products were sequenced on a
PRISM 3730xl automated DNA sequencer (Applied Biosystems).
Sequence data were assembled with the Phrap software program
(http://www.phrap.org), with conﬁrmatory assemblies performed
using CAP3 (Huang and Madan, 1999). The ﬁnal DNA consensus
sequence represented an average ﬁve-fold redundancy at each base
position. Sequence comparisons were conducted using BioEdit soft-
ware (http://www.mbio.ncsu.edu/BioEdit/bioedit.html).
Animal studies
First, 12 pigs were randomly allocated into 3 groups of 4 animals
each. Pigs in groups 1 and 2 were intranasally (IN) inoculated with 105
TCID50 FlagT4v, and pigs in group 3 were mock-infected. At 3 DPI
(group 1) or 28 DPI (group 2), animals were IN challenged with 105
TCID50 BICv along with animals in group 3. Clinical signs and body
temperature were recorded daily throughout the experiment as
previously described (Risatti et al., 2005b). Blood, serum, nasal
swabs and tonsil scrapings were collected at times post-challenge,
with blood obtained from the anterior vena cava in EDTA-containing
tubes (Vacutainer) for total and differential white blood cell counts.
Total and differential white blood cell and platelet counts were
obtained using a Beckman Coulter ACT (Beckman Fullerton, Coulter,
CA). Tissue samples were collected from animals at death or during
postmortem examination and processed as described before (Risatti et
al., 2005b).
To determine the earliest onset of FlagT4v protection swine were
allotted into 6 groups of 4 animals each. Five groups were
intramuscularly (IM) inoculated with 105 TCID50 of FlagT4v, and one
additional group was mock inoculated. All groups were then
challenged intranasally with 105 TCID50 of virulent BICv at day 0, 1,
2, 3, or 28 post-FlagT4v inoculation. Clinical evaluation and sampling
of animals was performed as described as Risatti et al., (2005b).
The presence of both FlagT4v and BICv was determined in target
organs including palatine tonsil, mandibular (MLN) and retrophar-
yngeal (RPLN) lymph nodes, and spleen at different time points after
infection. Three groups of animals were IN inoculatedwith 105 TCID50
of either FlagT4v (group 1, n=6) or BICv (group 2, n=6), or receivedFlagT4v followed by challenge with BICv at 3 DPI (group 3, n=8). Two
animals from groups 1 and 2 were euthanized at 3, 5 and 7 DPI. Pigs in
group 3 were euthanized at days 1, 3, 5, and 7 after receiving the BICv
challenge. Tissues were removed from all animals and stored at
−70 °C. Amount of virus in tissues was determined by virus titration in
SK6 cells as described above.
Detection of FlagT4v and BICv by immunoﬂuorescence
To assess the presence of FlagT4v and BICv in tonsils of infected/
challenged animals, palatine tonsil samples were collected postmor-
tem in triplicate. Tissues were mounted on polystyrene blocks using
Optimal Cutting Temperature (OCT) compound (TissueTek Sakura,
Torrance, CA), promptly frozen in liquid nitrogen, and stored at −70 °C.
Sections of 4 μm in thickness were obtained from each of the triplicate
cryopreserved tissue samples and ﬁxed with acetone for 10 min at
−20 °C. After ﬁxation, tissue sections were incubated at room
temperature (RT) for 90 min in blocking buffer containing 2% (w/v)
bovine serum albumin (Sigma) and 20% (v/v) normal bovine serum
(Gibco-Invitrogen, Carlsbad, CA) in PBS. Primary mAbs, anti-Flag M2
(Sigma), and WH303 were diluted in blocking buffer and incubated
with blocked tissue sections overnight at 4 °C in a humid chamber.
After washing ﬁve times with PBS at RT, tissue sections were
incubated for 90 min at 37 °C with the appropriate secondary
antibodies, goat anti-mouse isotype-speciﬁc IgG labeled with either
AlexaFluor 488 or AlexaFluor 594 (Molecular Probes-Invitrogen,
Carlsbad, CA) diluted in blocking buffer. After incubation, tissue
sections were washed 5 times with PBS at RT, counterstained with
TOPRO-iodide 642/661 (Molecular Probes) for 5 min at RT, washed 5
times with PBS at RT, mounted, and examined in a Leica Scanning
Confocal Microscope (Leica Microsystems, Bannockburn, IL). Data
were collected utilizing an appropriate control lacking incubation
with primary antibodies in order to determine channel crossover
settings, as well as using these antibodies in uninfected tissues to give
the negative background level. The captured images were adjusted for
contrast and brightness using Adobe Photoshop software (Adobe, San
José, CA).
Detection of anti-Flag antibodies
Serological antibody responses against the Flag epitope were
determined using an ELISA assay. ELISA plates (Immulon 2HB, Thermo
Scientiﬁc, West Palm Beach, FL) were coated with Amino-Terminal
3xFlagBAC protein (Sigma) at a concentration of 1 μg/ml diluted in
carbonate/bicarbonate buffer 0.05 M, pH 8.6 (Sigma) and incubated
overnight at 4 °C. Plates were blocked with blocking buffer [PBS
containing 5% (w/v) non-fat dry milk and 0.1% Tween-20 (v/v),
(Sigma)] for 1 h at 37 °C. Serum dilutions, performed in blocking
buffer, were incubated on the plates for 1 h at 37 °C. After washing 5
times with washing buffer (PBS containing 0.1% Tween-20) plates
were incubated with afﬁnity puriﬁed goat anti-swine IgG antibody
labeled with horseradish peroxidase (HRP) (KPL, Gaithersburg, MD)
diluted 1/1000 in blocking buffer for 1 h at 37 °C. After washing 5
times with washing buffer, plates were incubated with ABTS
Peroxidase Substrate System (KPL) and blocked with Peroxidase
Stop Solution (KPL). Readings were done at a wavelength of 405 nm in
an ELISA plate reader (Spectra). Titers were expressed as the log10 of
the inverse of the highest serum dilution that at least duplicate the OD
readings of a pool of naïve sera.
Detection of anti-mAbWH303e antibodies
Serological antibody responses against mAbWH303e were
detected using a competitive ELISA. ELISA plates (Immulon 2HB)
were coated with a synthetic peptide representing the mAbWH303e
(CTAVSPTTLRTEVVK) coupled to KLH (Celtek BioScience, Nashville,
113L.G. Holinka et al. / Virology 384 (2009) 106–113TN) at a concentration of 20 μg/ml diluted in carbonate/bicarbonate
buffer (Sigma) and incubated overnight at 4 °C. Plates were then
blocked with blocking buffer (see above) for 1 h at 37 °C. Serum
dilutions, performed in blocking buffer, were added to the plates along
with HRP labeled mAbWH303 (Covance, USA) followed by an
incubation step at room temperature for 90 min with shaking. After
washing 5 times with washing buffer, plates were incubated with
ABTS Peroxidase Substrate System (KPL) and blocked with Peroxidase
Stop Solution (KPL). Readings were done at a wavelength of 405 nm in
an ELISA plate reader.
Detection of BICv and FlagT4v by rtRT-PCR
ATaqMan® based duplex-rtRT-PCR assay was developed and used to
distinguish between BICv and FlagT4v. Primers and probes were
designed using Primer Express 3.0 software (Applied Biosystems, Foster
City, CA). A set of primers with a TET-labeled probe were designed to
target nucleotide sequence encoding for mAbWH303e within CSFV E2
glycoprotein. Primers BICv-DIVA1-F (5′AGGGTGGACGGGTGTTATAGA
GT3′) and BICv-DIVA1-R (5′TGAAGGTCTTTACCACTTCTGTTCTC3′) were
designed to target nucleotide sequences within BICv E2 glycoprotein
gene with the probe BICv-DIVA1-Pr (5′TET-CACGGCAGTGA-
GCCCGACAACTC3′TAMRA) targeting nucleotide sequence encoding for
the mAbWH303e. A second set of primers with a 6FAM-labeled probe
were designed to target the nucleotide sequence encoding for Flag
epitope inserted at the carboxyl terminal end of CSFV E1 glycoprotein.
Primer Flag-DIVA-F (5′GATTACAAGGATGACGACGATAAGG3′) targets a
region within E1 genes and Flag-DIVA-R (5′TTGTTGATATAGCG-
TACCTGTGATCTT3′) targets a region within E2 gene, while probe Flag-
DIVA-Pr (5′6FAM-CACAAGGCCGGCTAGCCTGCA3′TAMRA) targets the
Flag epitope. Viral RNA was obtained from BICv and FlagT4v using an
RNeasy kit (Qiagen, Valencia, CA). A one step rtRT-PCR was performed
using a TaqMan® EZ RT-PCR Core Reagent kit (Applied Biosystems). A
25 μl reaction was set combining, 500 nM of each of the BICv DIVA
primer set, 900 nM of each of the Flag-DIVA primer set, 75 nM of the
BICv-DIVA1-Pr, 250 nM of the Flag-DIVA-Pr, 10 mM dNTPs, 2.5 mMMn
(OAc), 5 μl of 5× TaqMan buffer, and 2.5 μl of template RNA (50 ng/ μl).
Cycling parameters were 60 °C for 10 min, followed by 45 cycles of
denaturation at 95 °C for 2 s and annealing-extension at 60 °C for 30 s.
Reactions were performed in a Smart Cycler instrument (Cepheid,
Sunnyville, CA). Fluorescent measurements were recorded during the
elongation step. Single rtRT-PCR assays were also performed with each
set of primers and probes against RNA from both FlagT4v and BICv to
assess assay speciﬁcity.
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